<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMM</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Medicine</journal-title></journal-title-group>
<issn pub-type="ppub">1107-3756</issn>
<issn pub-type="epub">1791-244X</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ijmm.2019.4077</article-id>
<article-id pub-id-type="publisher-id">ijmm-43-03-1331</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>MicroRNA-101 inhibits autophagy to alleviate liver ischemia/reperfusion injury via regulating the mTOR signaling pathway</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Song</surname><given-names>Hu</given-names></name><xref rid="af1-ijmm-43-03-1331" ref-type="aff">1</xref><xref rid="af2-ijmm-43-03-1331" ref-type="aff">2</xref><xref rid="fn1-ijmm-43-03-1331" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>Du</surname><given-names>Chenyang</given-names></name><xref rid="af1-ijmm-43-03-1331" ref-type="aff">1</xref><xref rid="af2-ijmm-43-03-1331" ref-type="aff">2</xref><xref rid="fn1-ijmm-43-03-1331" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Xingxing</given-names></name><xref rid="af1-ijmm-43-03-1331" ref-type="aff">1</xref><xref rid="af2-ijmm-43-03-1331" ref-type="aff">2</xref><xref rid="fn1-ijmm-43-03-1331" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhang</surname><given-names>Jianjun</given-names></name><xref rid="af1-ijmm-43-03-1331" ref-type="aff">1</xref><xref rid="af2-ijmm-43-03-1331" ref-type="aff">2</xref><xref rid="af3-ijmm-43-03-1331" ref-type="aff">3</xref><xref rid="af4-ijmm-43-03-1331" ref-type="aff">4</xref><xref ref-type="corresp" rid="c1-ijmm-43-03-1331"/></contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shen</surname><given-names>Zhongyang</given-names></name><xref rid="af1-ijmm-43-03-1331" ref-type="aff">1</xref><xref rid="af2-ijmm-43-03-1331" ref-type="aff">2</xref><xref rid="af3-ijmm-43-03-1331" ref-type="aff">3</xref><xref rid="af4-ijmm-43-03-1331" ref-type="aff">4</xref><xref ref-type="corresp" rid="c1-ijmm-43-03-1331"/></contrib></contrib-group>
<aff id="af1-ijmm-43-03-1331">
<label>1</label>First Central Clinical College, Tianjin Medical University, Tianjin 300070</aff>
<aff id="af2-ijmm-43-03-1331">
<label>2</label>Tianjin Key Laboratory for Organ Transplantation</aff>
<aff id="af3-ijmm-43-03-1331">
<label>3</label>Liver Transplantation Department, Tianjin First Center Hospital</aff>
<aff id="af4-ijmm-43-03-1331">
<label>4</label>Key Laboratory of Transplant Medicine, Chinese Academy of Medical Sciences, Tianjin 300192, P.R. China</aff>
<author-notes>
<corresp id="c1-ijmm-43-03-1331">Correspondence to: Professor Jianjun Zhang or Professor Zhongyang Shen, Liver Transplantation Department, Tianjin First Center Hospital, 24 Fukang Road, Tianjin 300192, P.R. China, E-mail: <email>yzxzhangjianjun@163.com</email>, E-mail: <email>zhongyangshen@vip.sina.com</email></corresp><fn id="fn1-ijmm-43-03-1331" fn-type="equal">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>03</month>
<year>2019</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>01</month>
<year>2019</year></pub-date>
<volume>43</volume>
<issue>3</issue>
<fpage>1331</fpage>
<lpage>1342</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>09</month>
<year>2018</year></date>
<date date-type="accepted">
<day>17</day>
<month>01</month>
<year>2019</year></date></history>
<permissions>
<copyright-statement>Copyright: &#x000A9; Song et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions>
<abstract>
<p>Liver ischemia/reperfusion injury (LIRI) is a common complication of liver surgery, and affects liver function post-transplantation. However, the precise mechanism underlying LIRI has not yet been completely elucidated. Previous studies have demonstrated the involvement of a number of microRNAs (miRNAs/miRs) in liver pathophysiology. The objective of the present study was to determine the potential function and mechanism of miR-101-mediated regulation of autophagy in LIRI. Compared with the sham-treated group, a significant decrease in miR-101 and mechanistic target of rapamycin (mTOR) expression levels following ischemia/reperfusion (IR) were observed, along with an increased number of autophagosomes (P&#x0003C;0.001). The exogenous overexpression of miR-101 has been demonstrated to inhibit autophagy during the LIRI response and the levels of mTOR and phosphorylated (p)-mTOR expression are correspondingly elevated. However, compared with the miR-NC group, miR-101 silencing was associated with reduced mTOR and p-mTOR levels and increased autophagy, as indicated by the gradual increase in the levels of the microtubule-associated protein 1 light II (LC3II). The peak levels of LC3II were observed 12 h subsequent to reperfusion, which coincided with the lowest levels of miR-101. In addition, inhibition of autophagy by 3-methyladenine significant enhanced the protective effect of miR-101 against LIRI, compared with the IR group (P&#x0003C;0.001). Altogether, miR-101 attenuates LIRI by inhibiting autophagy via activating the mTOR pathway.</p></abstract>
<kwd-group>
<kwd>liver ischemia/reperfusion injury</kwd>
<kwd>autophagy</kwd>
<kwd>microRNA-101</kwd>
<kwd>mechanistic target of rapamycin</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Liver ischemia/reperfusion injury (LIRI) is a common complication in liver surgery, and substantially influences the surgical outcome and patient prognosis (<xref rid="b1-ijmm-43-03-1331" ref-type="bibr">1</xref>-<xref rid="b3-ijmm-43-03-1331" ref-type="bibr">3</xref>). In previous years, the shortage of transplantation donors has increased the prevalence of marginal donors that further increase the risk of LIRI, and subsequently that of primary graft insufficiency or post-transplantation dysfunction (<xref rid="b4-ijmm-43-03-1331" ref-type="bibr">4</xref>,<xref rid="b5-ijmm-43-03-1331" ref-type="bibr">5</xref>). The mechanisms underlying LIRI pathology are highly complex and include the excessive production of reactive oxygen species, intracellular calcium overload, microvascular endothelial injury, inflammation and autophagy (<xref rid="b6-ijmm-43-03-1331" ref-type="bibr">6</xref>). It is essential to elucidate the exact molecular mechanism underlying LIRI, in order to protect the hepatocytes against ischemic injury.</p>
<p>Previous studies have revealed the involvement of microRNAs (miRNAs/miRs) in LIRI-associated autophagy (<xref rid="b7-ijmm-43-03-1331" ref-type="bibr">7</xref>&#x02013;<xref rid="b9-ijmm-43-03-1331" ref-type="bibr">9</xref>). miRNAs are non-coding RNAs ~21&#x02013;23 nucleotides long, and bind specifically to the 3&#x02032;-untranslated region (3&#x02032;-UTR) of the target mRNA, resulting in either mRNA degradation or a protein translation block (<xref rid="b10-ijmm-43-03-1331" ref-type="bibr">10</xref>,<xref rid="b11-ijmm-43-03-1331" ref-type="bibr">11</xref>). miRNAs may additionally mediate the upregulation of target mRNAs by direct activation and/or indirect derepression to enhance mRNA stability and translational activation (<xref rid="b12-ijmm-43-03-1331" ref-type="bibr">12</xref>). miRNAs have been implicated in various cellular and molecular events, including proliferation, differentiation and apoptosis, and the dysregulation of miRNAs is the mechanistic basis of various pathophysiological conditions (<xref rid="b13-ijmm-43-03-1331" ref-type="bibr">13</xref>,<xref rid="b14-ijmm-43-03-1331" ref-type="bibr">14</xref>). Previous studies have revealed a notable function of miR-101 in modulating autophagy. For example, Frankel <italic>et al </italic>(<xref rid="b15-ijmm-43-03-1331" ref-type="bibr">15</xref>) identified that miR-101 inhibited autophagy in breast cancer cells, whilst Valera <italic>et al </italic>(<xref rid="b16-ijmm-43-03-1331" ref-type="bibr">16</xref>) demonstrated that miR-101 induced multiple system atrophy via autophagy in the nervous system. In addition, Xu <italic>et al</italic> (<xref rid="b17-ijmm-43-03-1331" ref-type="bibr">17</xref>) concluded that miR-101 inhibited autophagy and enhanced cisplatin-induced apoptosis in hepatoma cells. The aim of the present study was to determine the function of miR-101 in mediating autophagy in LIRI, in order to identify a novel therapeutic target for LIRI.</p></sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title>Animals and cell lines</title>
<p>A total of 60 male C57BL/6 mice (7&#x02013;8 weeks old, weighing 20&#x02013;25 g) were obtained from the Experimental Animal Center of Academy of Military Medical Sciences (Beijing, China). All animals were maintained in an air-conditioned animal room at 25&#x000B0;C with free access to water and food, and exposed to a 12-h light/dark cycle. All animal experiments conformed to the National Institute of Health guidelines (<xref rid="b18-ijmm-43-03-1331" ref-type="bibr">18</xref>,<xref rid="b19-ijmm-43-03-1331" ref-type="bibr">19</xref>), and the animals were treated humanely. The study passed the ethical review of the Tianjin First Center Hospital (Tianjin, China) for the use of experimental animals, and the protocols were ethically approved by the ethics committee of Tianjin First Central Hospital. The non-tumorigenic mouse hepatocyte acute myeloid leukemia (AML)12 cell line was purchased from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China).</p></sec>
<sec>
<title>Reagents and antibodies</title>
<p>Fetal bovine serum, 0.05% trypsin-ethylenediaminetetraacetic acid and Dulbecco's modified Eagle's medium (DMEM)/F12 medium were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The miR-101 mimetics/inhibitor, miR-101 agomir/antagomir, miRNA negative control (miR-NC), and RiboFECTTM CP Reagent were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). Trizol and SYBR Green reverse transcription-quantitative polymerase chain reaction (RT-qPCR) Master Mix were purchased from Invitrogen (Thermo Fisher Scientific, Inc.) and Beijing Transgen Biotech Co., Ltd. (Beijing, China), respectively. The <italic>In Situ</italic> Cell Death Detection kit was purchased from Roche Diagnostics GmbH (Mannheim, Germany). An immunohistochemistry kit (cat. no. PV-9001) and DAB chromogenic kit (cat. no. ZLI-9018) were purchased from OriGene Technologies, Inc. (Beijing, China). The autophagy double-labeled adenovirus &#x0005B;m red fluorescence protein (RFP)-green fluorescence protein (GFP)-LC3&#x0005D; was acquired from Hanbio Biotechnology Co., Ltd. (Shanghai, China), and 3-methyladenine (3-MA) from Selleck Chemicals (Houston, TX, USA). Rapamycin (Rapa) and methylthiazole tetrazolium kit (MTT) were acquired from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Antibodies against mechanistic target of rapamycin (mTOR; cat. no. 2972), phosphorylated (p-)mTOR (cat. no. 2971), caspase-3 (cat. no. 9662), sequestosome 1/p62 (cat. no. 16177), microtubule-associated protein 1 light II (LC3II; cat. no. 3868), proliferating cell nuclear antigen (PCNA; cat. no. 13110) and GAPDH (cat. no. 5174), and the horseradish peroxidase (HRP)-conjugated anti-rabbit (cat. no. 7074) and anti-mouse (cat. no. 7076) secondary antibodies were all purchased from Cell Signaling Technology, Inc., (Danvers, MA, USA).</p></sec>
<sec>
<title>Establishment of an in vivo model of LIRI</title>
<p>This experiment established a segmental (70%) LIRI model according to a previous study (<xref rid="b20-ijmm-43-03-1331" ref-type="bibr">20</xref>), with the arterial and portal venous blood supply to the left and middle lobes interrupted using an atraumatic clip. Following 90 min of local ischemia, the clip was removed. Animals were sacrificed by dislocation of spine and harvested after 2, 6, 12 or 24 h reperfusion. Sham-operated mice underwent the same procedure, but without vascular occlusion as previous described (<xref rid="b20-ijmm-43-03-1331" ref-type="bibr">20</xref>). The mice were randomized into the following 10 groups (n=6/group): A control/sham operated group, 4 untreated LIRI groups with different reperfusion times (2, 6, 12 and 24 h) and 5 LIRI groups that were administered an intravenous injection 24 h prior to ischemia and harvested subsequent to 12 h reperfusion, with injections consisting of the following: i) 10 nM miR-101 agomir, ii) 10 nM miR-101 antagomir, iii) 10 nM miR-NC, iv) 5 mg/kg 3-MA and v) miR-101 agomir plus 3-MA. The 3-MA was intraperitoneally administered 1 h prior to ischemia.</p></sec>
<sec>
<title>Serological tests</title>
<p>Blood was collected from the mice from their inferior vena cava and centrifuged (4&#x000B0;C, 15 min, 1,000 &#x000D7; g) to collect the serum. The levels of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined using commercial assay kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) and according to the manufacturer's protocol. Enzyme activity was expressed as international units per liter (U/I).</p></sec>
<sec>
<title>Hematoxylin and eosin (H&#x00026;E) staining</title>
<p>The liver tissues were fixed in 4% formalin for 48 h at 4&#x000B0;C, embedded in paraffin blocks and processed into 4-<italic>&#x000B5;</italic>m-thick sections. The slides were then dehydrated using an ethanol gradient (100% for 10 min, 95% at 10 min and 80% for 10 min) and de-paraffinized using xylene. H&#x00026;E staining was performed according to a standard procedure (<xref rid="b21-ijmm-43-03-1331" ref-type="bibr">21</xref>), and the histopathological changes were observed under a light microscope at a magnification of &#x000D7;200. IR-induced liver damage was quantified by measuring the Suzuki score as presented in <xref rid="tI-ijmm-43-03-1331" ref-type="table">Table I</xref> and a previous study (<xref rid="b22-ijmm-43-03-1331" ref-type="bibr">22</xref>).</p></sec>
<sec>
<title>Immunohistochemistry</title>
<p>Paraffin sections of liver tissue were cut into 4-<italic>&#x000B5;</italic>m-thick sections and dehydrated, cleared using xylene and heated to 95&#x000B0;C using 0.01 mol/l citrate buffer solution (pH 6.0) in a water bath for antigen retrieval. Subsequent to blocking with 5% goat serum (Solarbio Science &#x00026; Technology Co., Ltd., Beijing, China) for 1 h at room temperature, the sections were incubated with rabbit anti-mouse PCNA and caspase-3 polyclonal antibodies (both dilution, 1:1,000; Cell Signaling Technology, Inc.) overnight at 4&#x000B0;C. Then sections were incubated with enzyme-labeled goat anti-rabbit immunoglobulin G (IgG) polymer from the immunohistochemistry kit for 1 h at room temperature. In total, 0.5 ml DAB staining solution A, 0.5 ml DAB staining solution B and 1 ml DAB staining working solution were prepared and gently mixed. The sections were incubated with the mixture at 20&#x02013;25&#x000B0;C for 5 min, and the sections were counterstained with 10% hematoxylin for 30 sec at room temperature. The stained slides were washed thoroughly in running tap water, dehydrated and mounted with cover slips. Hepatocytes positively stained for PCNA and caspase-3 were examined under a light microscope at a magnification of &#x000D7;200, and ImageJ 1.48v software (National Institutes of Health, Bethesda, MD, USA) was used to analyze the area occupied by the positively stained cells.</p></sec>
<sec>
<title>Terminal uridine nick-end labeling (TUNEL) assay</title>
<p>The <italic>In Situ</italic> Cell Death Detection kit (with TMR red as the fluorescence marker) was used to detect TUNEL positive apoptotic cells according to the manufacturer's protocol. Apoptosis was observed under fluorescence microscope at a magnification of &#x000D7;200. The area occupied by the positive cells was analyzed using Image J 1.48v software.</p></sec>
<sec>
<title>Cell culture and transfection</title>
<p>AML12 cells were plated at a density of 2&#x000D7;10<sup>5 </sup>cells/ml in 6-well plates and divided into 4 treatment groups, as followings: i) A control untreated group; ii) an ischemia/reperfusion (IR) group subjected to hypoxia for 1 h to simulate ischemia and then cultured in DMEM/F12 for 12 h to simulate reperfusion; iii) an miR-101 mimetics group transfected with 50 nM miR-101 mimetics or miR-NC using RiboFECTTM for 48 h at 37&#x000B0;C, and subjected to hypoxia/reperfusion 48 h later; and iv) miR-101 inhibitor group transfected with 50 nM miR-101 inhibitor or miR-NC, and subjected to hypoxia/reperfusion 48 h later. To induce hypoxia, the culture medium was removed 48 h after transfection and replaced with 2 ml Hank's solution (Thermo Fisher Scientific, Inc.), and the cells were placed in a low oxygen incubator. After 1.5 h, Hank's solution was removed and replaced with 2 ml DMEM/F12 medium, and the cells were cultured under normal oxygen tension (with 5% CO<sub>2</sub>) for 12 h to simulate the reperfused (re-oxygenated) state.</p></sec>
<sec>
<title>Confocal fluorescence microscopy</title>
<p>AML12 cells were plated in 24-well plates, and cultured until they reached 60&#x02013;70% confluence. The cells were transduced with the GFP-RFP-LC3 adenovirus (3&#x000D7;10<sup>7 </sup>PFU/well) for 48 h at 37&#x000B0;C according to the manufacturer's protocol to induce autophagy and the resulting autophagosomes were observed under a confocal microscope at a magnification of &#x000D7;1,000. The number of autophagosomes in each cell was counted, and the mean number of autophagosomes of all cells was calculated to determine the autophagic degree of each treatment group.</p></sec>
<sec>
<title>RT-qPCR</title>
<p>Total RNA was extracted from tissues or cells using TRIzol total RNA isolation reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Subsequently, the PrimeScript RT reagent kit (Beijing Transgen Biotech Co., Ltd.) was used for RT of the RNA into cDNA, according to the manufacturer's protocol. SYBR-Green RT-qPCR Master Mix was used as the flurophore. RT-qPCR was performed using specific primers for miR-101 (forward, 5&#x02032;-GTACAGTACTGTGATAACTGA-3&#x02032; and reverse, 5&#x02032;-TGCGTGTCGTGGAGTC-3&#x02032;), mTOR (forward, 5&#x02032;-TCGGTGCAAACCTACAGAAGC-3&#x02032; and reverse, 5&#x02032;-TGCAGGTCGTATATGGACAGAG-3&#x02032;) and GAPDH (forward, 5&#x02032;-GGAGCGAGATCCCTCCAAAAT-3&#x02032; and reverse, 5&#x02032;-GGCTGTTGTCATACTTCTCATGG-3&#x02032;) used as the internal control. The thermocycling conditions were as follows: Pre-denaturation at 94&#x000B0;C for 30 sec, followed by 45 cycles of denaturation at 94&#x000B0;C for 5 sec, annealing at 60&#x000B0;C for 15 sec and extension at 72&#x000B0;C for 10 sec. Each sample was tested in quadruplicates. The relative expression of each gene was quantified using the comparative quantification cycle method as follows: Copy number of target gene = 2<sup>&#x02212;&#x00394;&#x00394;Cq</sup>, &#x00394;Cq = C<sub>qtarget gene</sub>&#x02212;Cq<sub>reference gene</sub>, &#x00394;&#x00394;Cq = &#x00394;Cq<sub>experimental group</sub>&#x02212;&#x00394;Cq<sub>control group</sub> (<xref rid="b23-ijmm-43-03-1331" ref-type="bibr">23</xref>).</p></sec>
<sec>
<title>Immunofluorescence</title>
<p>AML12 cells were transfected with miR-101 mimetics or miR-101 inhibitors using RiboFECTTM for 48 h at 37&#x000B0;C, according to the reagent manufacturer's protocol. Following differentiation and treatments, cells were fixed with 4% paraformaldehyde for 15 min at room temperature and permeabilized with 0.1% Triton X-100 for 5 min at room temperature. Cells were then incubated for 60 min at room temperature with blocking solution (5% goat serum) followed by overnight incubation at 4&#x000B0;C with anti-p62 antibodies (dilution, 1:800) Following washing with PBS, cells were incubated with fluorescence-labeled secondary antibodies (Alexa Fluor<sup>&#x000AE;</sup> 594-conjugated goat polyclonal anti-rabbit; 1:500; cat. no. 8889; Cell Signaling Technology, Inc.) for 1 h at room temperature in the dark. In addition, DAPI (1:1,000; cat. no. D9564; Sigma-Aldrich; Merck KGaA) was used to non-specifically stain the nuclei and samples were incubated with 50 <italic>&#x000B5;</italic>l DAPI for 10 min at room temperature. Immunostaining was visualized under a fluorescence microscope at a magnification of &#x000D7;400.</p></sec>
<sec>
<title>MTT bioassay</title>
<p>AML12 cells were seeded into 96-well plates (5&#x000D7;10<sup>4</sup> cells/well) and after 24 h culturing, were treated with Rapa or 3-MA for 2 h, or miR-101 inhibitor for 48 h at 37&#x000B0;C prior to reperfusion. Fresh medium was then added to each well along with 20 <italic>&#x000B5;</italic>l MTT solution (5 mg/ml), and the cells were incubated for another 4 h at 37&#x000B0;C. The medium was then removed, and 200 <italic>&#x000B5;</italic>l dimethylsulfoxide was added per well to stop the reaction. The optical density of each well was determined at 490 nm.</p></sec>
<sec>
<title>Western blot analysis</title>
<p>Radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) were used to extract the total protein from AML12 cells and liver tissues. The protein concentration was determined by Bicinchoninic Acid Protein Assay kit (Solarbio Science &#x00026; Technology Co., Ltd.). Equal samples of protein (30 <italic>&#x000B5;</italic>g) were separated by SDS-PAGE on 12% gels and transferred onto a polyvinylidene difluoride membrane. The membrane was blocked with 5% skim milk for 1 h at room temperature. The membrane was then incubated with mTOR, p-mTOR, GAPDH, LC3 II, caspase-3 and p62 (all 1:1,000) primary antibodies overnight at 4&#x000B0;C. The membranes were then washed with TBS-Tween-20 at room temperature (5 min/wash). Subsequently, the membrane was treated with HRP-conjugated goat anti-rabbit and anti-mouse IgG secondary antibodies (both 1:2,500), agitated and incubated at room temperature for 1 h. The protein bands were visualized by using a G:BOX imaging system (Gene Company, Ltd., Hong Kong, China). The protein bands were measured with ImageJ 1.48v software and normalized to the corresponding GAPDH bands. The relative density of each target protein normalized to the control was used to represent the changes in expression of target proteins.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Statistical analysis was performed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA). Normally distributed data were expressed as the mean &#x000B1; standard deviation (x&#x000B1;s). A Student's t test was used for comparing two groups, a one-way analysis of variance for comparing multiple groups and the Least-Significant-Difference method was used as a post-hoc test for multiple comparisons between groups. P&#x0003C;0.05 was considered to indicate a statistically significant difference.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>LIRI alters the expression of miR-101 and mTOR in mouse liver</title>
<p>The expression levels of miR-101 and mTOR mRNA initially significantly increased following reperfusion compared with their respective sham groups (P&#x0003C;0.001), but significantly decreased in the liver of the IR mouse model following reperfusion at 6 and 12 h compared with the respective sham groups (P&#x0003C;0.001; <xref rid="f1-ijmm-43-03-1331" ref-type="fig">Fig. 1A</xref>).</p></sec>
<sec>
<title>LIRI alters serum AST and ALT levels</title>
<p>The levels of serum AST and ALT were significantly increased following reper-fusion in a time-dependent manner compared with the sham groups (P&#x0003C;0.001). Compared with the sham-treated group, the IR mice exhibited a gradual increase in the serum AST and ALT levels that peaked at 12 h (P&#x0003C;0.001; <xref rid="f1-ijmm-43-03-1331" ref-type="fig">Fig. 1B</xref>).</p></sec>
<sec>
<title>LIRI affects apoptosis and autophagy</title>
<p>As presented in <xref rid="f1-ijmm-43-03-1331" ref-type="fig">Fig. 1C</xref>, LC3II expression levels significantly increased following 6 and 12 h reperfusion and peaked at 12 h compared with the sham group (P&#x0003C;0.01) and the pro-apoptotic caspase-3 was also significantly upregulated following reperfusion with maximum expression at 12 h post-reperfusion compared with the sham group (P&#x0003C;0.05). Although the expression levels of mTOR and p62 increased after 2 h reperfusion, the expression levels of mTOR, p-mTOR and p62 significantly decreased steadily in a time-dependent manner following reperfusion at 6, 12 and 24 h (P&#x0003C;0.05).</p></sec>
<sec>
<title>Histopathological changes in the liver following IRI</title>
<p>The liver tissues of the IR mice demonstrated edema, ballooning, steatosis, flaky necrosis, neutrophil infiltration and congestion, in addition to the disappearance of the hepatic sinusoidal structure in certain areas. These lesions were substantially aggravated with time, with the severest injuries observed at 12 h after reperfusion, but were relieved at 24 h post-reperfusion. In addition, IR-induced liver damage was quantified by measuring the Suzuki score, which gradually significantly increased following reperfusion compared with the sham group (P&#x0003C;0.01; <xref rid="f2-ijmm-43-03-1331" ref-type="fig">Fig. 2A</xref>).</p></sec>
<sec>
<title>IRI alters proliferation and apoptosis of liver cells</title>
<p>Compared with the sham-treated group (<xref rid="f2-ijmm-43-03-1331" ref-type="fig">Fig. 2B</xref>), the intra-nuclear expression of the proliferative marker PCNA significantly decreased following reperfusion at the 6 and 12 h mark, despite initially increasing at the 2 h mark and again increasing at the 24 h mark (P&#x0003C;0.01). The cytoplasmic expression of caspase-3 gradually significantly increased in the liver cells of IR mice with time compared with the sham group (P&#x0003C;0.001) and a peak change was observed 12 h after reperfusion. Additionally, as presented in <xref rid="f2-ijmm-43-03-1331" ref-type="fig">Fig. 2C</xref>, the number of TUNEL-positive apoptotic cells were also significantly higher in the IR groups compared with the sham-treated group (P&#x0003C;0.05). The apoptotic changes were time dependent, with peak alterations observed 12 h after reperfusion.</p></sec>
<sec>
<title>miR-101 weakens LIRI by inhibiting apoptosis</title>
<p>As presented in <xref rid="f3-ijmm-43-03-1331" ref-type="fig">Fig. 3A</xref>, the expression levels of mTOR in the miR-101 agomir group were significantly increased compared with the mTOR miR-NC group (P&#x0003C;0.001), while the expression levels of mTOR in the mir-101 antagomir group were significantly decreased compared with the mTOR miR-NC group (P&#x0003C;0.01; <xref rid="f3-ijmm-43-03-1331" ref-type="fig">Fig. 3A</xref>). The miR-101 antagomir significantly aggravated the histopatho-logical changes in the liver and the corresponding Suzuki scores induced by IR treatment, while miR-101 agomir significantly alleviated these changes compared with the miR-101 miR-NC group (P&#x0003C;0.001; <xref rid="f3-ijmm-43-03-1331" ref-type="fig">Fig. 3B</xref>). The overexpression of miR-101 significantly reduced the expression of LC3II and caspase-3 compared with the miR-101 miR-NC group (P&#x0003C;0.001) and significantly increased that of mTOR compared with the miR-101 miR-NC group (P&#x0003C;0.01; <xref rid="f3-ijmm-43-03-1331" ref-type="fig">Fig. 3C</xref>). IR-induced apoptosis was significantly increased by miR-101 antagomir compared with the miR-NC group (P&#x0003C;0.05) and alleviated by miR-101 agomir compared with the miR-NC group (P&#x0003C;0.01; <xref rid="f3-ijmm-43-03-1331" ref-type="fig">Fig. 3D</xref>).</p></sec>
<sec>
<title>Inhibition of autophagy enhances the protective effect of miR-101 on LIRI</title>
<p>Treatment of the IR mice with the autophagy inhibitor 3-MA in addition to miR-101 transfection significantly reduced the IR-induced histopathological changes and Suzuki scores compared with the IR group (P&#x0003C;0.001; <xref rid="f4-ijmm-43-03-1331" ref-type="fig">Fig. 4A</xref>) and significantly increased the nuclear expression of PCNA compared with the untreated IR group (P&#x0003C;0.001; <xref rid="f4-ijmm-43-03-1331" ref-type="fig">Fig. 4B</xref>). In addition, IR-induced apoptosis was significantly reduced in the mice treated with miR-101+3-MA compared with the untreated IR group (P&#x0003C;0.001; <xref rid="f4-ijmm-43-03-1331" ref-type="fig">Fig. 4C</xref>) and validated by the significantly lower expression levels of caspase-3 and LC3II and the upregulation in p62 levels compared with the IR group (P&#x0003C;0.001; <xref rid="f4-ijmm-43-03-1331" ref-type="fig">Fig. 4D</xref>). Serum AST and ALT levels were also significantly lower in the miR-101+3-MA group compared with the IR group (P&#x0003C;0.001; <xref rid="f4-ijmm-43-03-1331" ref-type="fig">Fig. 4E</xref>).</p></sec>
<sec>
<title>miR-101 inhibits autophagy and weakens LIRI by activating the mTOR pathway in vitro</title>
<p>As presented in <xref rid="f5-ijmm-43-03-1331" ref-type="fig">Fig. 5</xref>, the expression levels of mTOR in the miR-101 mimetics group were significantly increased compared with the mTOR NC group (P&#x0003C;0.001), while the expression level of mTOR in the miR-101 inhibitor group was significantly decreased compared with the mTOR NC group (P&#x0003C;0.01; <xref rid="f5-ijmm-43-03-1331" ref-type="fig">Fig. 5A</xref>). In addition, the overexpression of miR-101 significantly reduced the expression of LC3II and caspase-3 compared with the NC group (P&#x0003C;0.05; <xref rid="f5-ijmm-43-03-1331" ref-type="fig">Fig. 5B</xref>). The Ad-GFP-RFP-LC3 system was used to determine the potential function of miR-101 in modulating autophagy subsequent to simulated-IR in AML12 cells. The presence of co-localized GFP-LC3 or RFP-LC3 granules indicate the recruitment of the LC3 protein to autophagosomes, which are formed when autophagy is triggered (<xref rid="b24-ijmm-43-03-1331" ref-type="bibr">24</xref>). When autophagosomes fuse with lysosomes and form autolysosomes, GFP but not RFP degrades in the acidic environment, resulting in solely red granules (<xref rid="b25-ijmm-43-03-1331" ref-type="bibr">25</xref>). As presented in <xref rid="f5-ijmm-43-03-1331" ref-type="fig">Fig. 5C</xref>, the number of autophagosomes in the miR-101 mimetics group was significantly lower compared with that in the IR group (P&#x0003C;0.001), indicating that miR-101 inhibits autophagy. Furthermore, the number of autophagosomes significantly increased upon miR-101 inhibition compared with that in the IR group (P&#x0003C;0.05). In addition, p62 was upregulated in the miR-101 mimetics group and was downregulated in the miR-101 inhibitor group compared with the NC group (<xref rid="f5-ijmm-43-03-1331" ref-type="fig">Fig. 5D</xref>). Altogether, the overexpression of miR-101 inhibited the formation of autophagosomes and autolysosomes, and thus attenuated autophagy.</p></sec>
<sec>
<title>Inhibition of miR-101 and mTOR expression aggravates LIRI</title>
<p>Reperfusion was established following the pre-treatment of AML12 cells with miR-101 inhibitor and mTOR inhibitor rapamycin. The expression of LC3II and caspase-3 were significantly increased compared with the IR group (P&#x0003C;0.001; <xref rid="f6-ijmm-43-03-1331" ref-type="fig">Fig. 6A</xref>), and the percentage of viable cells was significantly decreased following co-suppression compared with the IR group (P&#x0003C;0.001; <xref rid="f6-ijmm-43-03-1331" ref-type="fig">Fig. 6B</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Liver transplantation is the only treatment option currently available for end-stage liver disease. Unfortunately, it is associated with various complications, including LIRI, which is a common pathophysiological consequence of liver surgery (<xref rid="b26-ijmm-43-03-1331" ref-type="bibr">26</xref>). The mechanism of LIRI is complex, and is closely associated with inflammation, metabolic disorders, oxidative stress and autophagy. In addition, each of these factors may be mutually antagonistic or synergistic (<xref rid="b27-ijmm-43-03-1331" ref-type="bibr">27</xref>).</p>
<p>Autophagy is an intracellular self-digestion pathway present in the majority of eukaryotic cells, which helps in organelle recycling and fulfils cellular metabolic requirements under stress conditions (<xref rid="b28-ijmm-43-03-1331" ref-type="bibr">28</xref>). The autophagy-related genes (Atgs) induce the detachment of bilayer membrane structures from the rough endoplasmic reticulum, which then encapsulate organelles and other cytoplasmic contents to form autophagosomes. The latter then fuse with lysosomes to form autolysosomes, and the intra-vesicular contents are degraded by the lysosomal enzymes (<xref rid="b29-ijmm-43-03-1331" ref-type="bibr">29</xref>). LC3/Atg8 is a marker of the autophagosome membrane, and the conversion of LC3I to LC3II is used as a measure of autophagosome formation (<xref rid="b30-ijmm-43-03-1331" ref-type="bibr">30</xref>). One previous study has demonstrated that hepatic autophagy is notably enhanced in LIRI models (<xref rid="b31-ijmm-43-03-1331" ref-type="bibr">31</xref>), but the underlying mechanism is not fully understood. Autophagy functions as a double-edged sword in hepatic IR and influences cell survival and apoptosis (<xref rid="b32-ijmm-43-03-1331" ref-type="bibr">32</xref>). In moderate IRI, the autophagosomes digest damaged organelles and provide energy to the cells. However, severe reperfusion injury results in excessive autophagy, which may trigger cell death (<xref rid="b33-ijmm-43-03-1331" ref-type="bibr">33</xref>). Therefore, targeting the autophagy pathway may effectively protect against IRI (<xref rid="b34-ijmm-43-03-1331" ref-type="bibr">34</xref>).</p>
<p>In previous years, studies have focused on the function of miRNAs in hepatic IRI, particularly their involvement in autophagy (<xref rid="b35-ijmm-43-03-1331" ref-type="bibr">35</xref>&#x02013;<xref rid="b37-ijmm-43-03-1331" ref-type="bibr">37</xref>). miRNAs are able to regulate autophagy by inhibiting the expression of target genes, which in turn affect IRI (<xref rid="b13-ijmm-43-03-1331" ref-type="bibr">13</xref>). Previous studies have demonstrated that miR-17 upregulated autophagy and aggravated the degree of LIRI by inhibiting Stat3 expression in LIRI (<xref rid="b31-ijmm-43-03-1331" ref-type="bibr">31</xref>), while miR-30b reduced autophagy and protected against LIRI by inhibiting Atg12-Atg5 binding (<xref rid="b38-ijmm-43-03-1331" ref-type="bibr">38</xref>). Studies have additionally demonstrated that the inhibition of miR-34a enhanced sirtuin 1 expression, which downregulated autophagy and subsequently protected the liver from p65/p53 deacetylation-induced damage (<xref rid="b39-ijmm-43-03-1331" ref-type="bibr">39</xref>,<xref rid="b40-ijmm-43-03-1331" ref-type="bibr">40</xref>). Therefore, the miRNAs regulating autophagy in LIRI may be potential therapeutic targets. miRNAs typically function by causing mRNA degradation through interacting with the 3&#x02032;-UTR of the target mRNAs, resulting in mRNA degradation and/or translational repression (<xref rid="b12-ijmm-43-03-1331" ref-type="bibr">12</xref>). Conversely, the miRNA-mediated upregulation of target mRNAs may be elucidated by direct activation and/or indirect derepression to enhance mRNA stability and translational activation (<xref rid="b41-ijmm-43-03-1331" ref-type="bibr">41</xref>). Studies have demonstrated that in miRNA-mediated upregulation, micro-ribonucleoprotein (miRNP) trans-expression promotes the expression of its target mRNA, which is similar to miRNA-mediated downregulation (<xref rid="b42-ijmm-43-03-1331" ref-type="bibr">42</xref>-<xref rid="b44-ijmm-43-03-1331" ref-type="bibr">44</xref>). MRNA expression may be activated directly by miRNP and/or alleviated indirectly from miRNA-mediated inhibition by eliminating the inhibitory effect of miRNP (<xref rid="b45-ijmm-43-03-1331" ref-type="bibr">45</xref>).</p>
<p>The present study investigated whether miR-101 was able to affect autophagy and serve a function in LIRI through the mTOR pathway. In previous studies, miR-101 was able to inhibit tumor growth by inhibiting autophagy (<xref rid="b46-ijmm-43-03-1331" ref-type="bibr">46</xref>&#x02013;<xref rid="b48-ijmm-43-03-1331" ref-type="bibr">48</xref>). mTOR is a notable serine-threonine protein kinase downstream of phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) (<xref rid="b49-ijmm-43-03-1331" ref-type="bibr">49</xref>) and inhibits autophagy during tumor growth and progression (<xref rid="b17-ijmm-43-03-1331" ref-type="bibr">17</xref>,<xref rid="b47-ijmm-43-03-1331" ref-type="bibr">47</xref>). Li <italic>et al</italic> (<xref rid="b50-ijmm-43-03-1331" ref-type="bibr">50</xref>) revealed that octreotide is able to upregulate the expression of miR-101 and inhibit autophagy by inactivating AMP-activated protein kinase (AMPK) and activating the mTOR pathway, thereby reducing the incidence of intestinal mucositis following anticancer treatment. However, little is known regarding the function of the miR101/mTOR axis in LIRI.</p>
<p>The present study revealed that IRI induced a number of pathological, functional and molecular changes in the liver, including increased serum levels of ALT and AST, the downregulation of miR-101, mTOR mRNA and p62, increased levels of LC3II and caspase-3, decreased intra-nuclear PCNA and extensive tissue necrosis and apoptosis. PCNA is closely associated with cellular DNA synthesis and therefore a good indicator of cell proliferation status (<xref rid="b51-ijmm-43-03-1331" ref-type="bibr">51</xref>,<xref rid="b52-ijmm-43-03-1331" ref-type="bibr">52</xref>). Caspase-3 is a necessary terminal cleavage enzyme in the intrinsic apoptotic pathway, and an established indicator of apoptosis (<xref rid="b53-ijmm-43-03-1331" ref-type="bibr">53</xref>).</p>
<p>Based on the results of the present study, miR-101 was negatively associated with autophagy. Furthermore, the over-expression of miR-101 reduced apoptosis, increased mTOR expression and decreased LC3II and caspase-3 levels, whilst the inhibition of miR-101 had the reverse effects. In addition, the inhibition of autophagy by 3-MA augmented the protective effects of miR-101 overexpression against LIRI.</p>
<p>To assess the hypothesis that miR-101 regulates the mTOR signaling pathway, the present study investigated the function of miR-101 in the regulation of the mTOR signaling pathway. The overexpression of miR-101 in LIRI-mimicking AML12 cells increased mTOR expression, decreased the number of autophagosomes and increased p62 expression. miR-101 inhibition exhibited the reverse effects on mTOR expression and autophagosome formation. Subsequently, miR-101 and mTOR were co-inhibited in AML12 cells, and it resulted in an increase in autophagy and cell death. These results indicate that miR-101 protects hepatocytes against IR injury by inhibiting autophagy via activation of mTOR signaling pathway.</p>
<p>The present study identified the inhibitory effect of miR-101 on autophagy in LIRI by regulating the expression of mTOR. But, a number of limitations of the present study should be taken into consideration. For example, the underlying mechanisms of the inductory effect of miR-101 on mTOR should be further studied. However, microRNA regulation is multi-directional. Nikoonahad <italic>et al</italic> (<xref rid="b54-ijmm-43-03-1331" ref-type="bibr">54</xref>) revealed that miR-101 inhibits the growth of AML cancer cells by directly upregulating the expression of the pro-apoptotic gene Bcl2 like11 (BIM). Different diseases and different conditions may cause miRNAs to exhibit distinct regulatory mechanisms. In addition, as one of the substrates of Akt, the P13K/Akt/mTOR regulatory pathway has been confirmed to serve a necessary function in cell growth and regulation (<xref rid="b55-ijmm-43-03-1331" ref-type="bibr">55</xref>). At present, the function of miR-101 in LIRI through the P13K/Akt/mTOR regulatory pathway remains to be further verified. AMPK is a cellular energy receptor, and a number of studies have demonstrated that AMPK is a negative regulator of the mTOR pathway (<xref rid="b56-ijmm-43-03-1331" ref-type="bibr">56</xref>,<xref rid="b57-ijmm-43-03-1331" ref-type="bibr">57</xref>). Studies have also revealed that miR-101 may inhibit the action of AMPK by directly targeting the 3&#x02032;-UTR region of AMPK (<xref rid="b58-ijmm-43-03-1331" ref-type="bibr">58</xref>,<xref rid="b59-ijmm-43-03-1331" ref-type="bibr">59</xref>). Therefore, miR-101 is likely to regulate the mTOR signaling pathway and serve a function in LIRI by affecting the expression of AMPK. Whether miR-101 affects the expression of mTOR by regulating AMPK in LIRI and whether there are other regulatory objectives and mechanisms has yet to be further studied.</p>
<p>In conclusion, the present study revealed that miR-101 attenuates LIRI by activating the mTOR pathway and inhibiting autophagy. Further studies are required to further dissect the association between autophagy and miRNAs in hepatocytes following IR in order to develop novel therapies.</p></sec></body>
<back>
<sec sec-type="other">
<title>Funding</title>
<p>The present study was supported by the Tianjin Clinical Research Center for Organ Transplantation Project (grant no. 15ZXLCSY00070).</p></sec>
<sec sec-type="materials">
<title>Availability of data and materials</title>
<p>The datasets used and analyzed during the present study are available from the corresponding author on reasonable request.</p></sec>
<sec sec-type="other">
<title>Authors' contributions</title>
<p>HS and JZ conceived and designed the experiments. HS, CD and XW performed the experiments. HS, JZ and ZS analyzed the data. HS and CD wrote the paper. All authors read and approved the final manuscript.</p></sec>
<sec sec-type="other">
<title>Ethics approval and consent to participate</title>
<p>The use and care of the animal were in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (<xref rid="b18-ijmm-43-03-1331" ref-type="bibr">18</xref>). The research protocols were approved by the Ethics Committee of Tianjin First Center Hospital (Tianjin, China).</p></sec>
<sec sec-type="other">
<title>Patient consent for publication</title>
<p>Not applicable.</p></sec>
<sec sec-type="other">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p></sec>
<ack>
<title>Acknowledgments</title>
<p>Not applicable.</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ijmm-43-03-1331"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cursio</surname><given-names>R</given-names></name><name><surname>Colosetti</surname><given-names>P</given-names></name><name><surname>Gugenheim</surname><given-names>J</given-names></name></person-group><article-title>Autophagy and liver ischemia-reperfusion injury</article-title><source>Biomed Res Int</source><volume>2015</volume><fpage>417590</fpage><year>2015</year><pub-id pub-id-type="doi">10.1155/2015/417590</pub-id><pub-id pub-id-type="pmid">25861623</pub-id><pub-id pub-id-type="pmcid">4377441</pub-id></element-citation></ref>
<ref id="b2-ijmm-43-03-1331"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rautou</surname><given-names>PE</given-names></name><name><surname>Mansouri</surname><given-names>A</given-names></name><name><surname>Lebrec</surname><given-names>D</given-names></name><name><surname>Durand</surname><given-names>F</given-names></name><name><surname>Valla</surname><given-names>D</given-names></name><name><surname>Moreau</surname><given-names>R</given-names></name></person-group><article-title>Autophagy in liver diseases</article-title><source>J Hepatol</source><volume>53</volume><fpage>1123</fpage><lpage>1134</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.jhep.2010.07.006</pub-id><pub-id pub-id-type="pmid">20810185</pub-id></element-citation></ref>
<ref id="b3-ijmm-43-03-1331"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>PX</given-names></name><name><surname>Zhu</surname><given-names>LH</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Mindin deficiency protects the liver against ischemia/reperfusion injury</article-title><source>J Hepatol</source><volume>63</volume><fpage>1198</fpage><lpage>1211</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.jhep.2015.06.033</pub-id><pub-id pub-id-type="pmid">26165142</pub-id></element-citation></ref>
<ref id="b4-ijmm-43-03-1331"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavien</surname><given-names>PA</given-names></name></person-group><article-title>How far can we go with marginal donors?</article-title><source>J Hepatol</source><volume>45</volume><fpage>483</fpage><lpage>484</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.jhep.2006.07.015</pub-id><pub-id pub-id-type="pmid">16908085</pub-id></element-citation></ref>
<ref id="b5-ijmm-43-03-1331"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halazun</surname><given-names>KJ</given-names></name><name><surname>Quillin</surname><given-names>RC</given-names></name><name><surname>Rosenblatt</surname><given-names>R</given-names></name><name><surname>Bongu</surname><given-names>A</given-names></name><name><surname>Griesemer</surname><given-names>AD</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Michelassi</surname><given-names>F</given-names></name><name><surname>Guarrera</surname><given-names>JV</given-names></name><name><surname>Samstein</surname><given-names>B</given-names></name><etal/></person-group><article-title>Expanding the margins: High volume utilization of marginal liver grafts among &#x02265;2000 liver transplants at a single institution</article-title><source>Ann Surg</source><volume>266</volume><fpage>441</fpage><lpage>449</lpage><year>2017</year><pub-id pub-id-type="doi">10.1097/SLA.0000000000002383</pub-id><pub-id pub-id-type="pmid">28657945</pub-id></element-citation></ref>
<ref id="b6-ijmm-43-03-1331"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentsch</surname><given-names>AB</given-names></name><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Yoshidome</surname><given-names>H</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Edwards</surname><given-names>MJ</given-names></name></person-group><article-title>Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury</article-title><source>Hepatology</source><volume>32</volume><fpage>169</fpage><lpage>173</lpage><year>2000</year><pub-id pub-id-type="doi">10.1053/jhep.2000.9323</pub-id><pub-id pub-id-type="pmid">10915720</pub-id></element-citation></ref>
<ref id="b7-ijmm-43-03-1331"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group><article-title>Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation</article-title><source>J Cell Mol Med</source><volume>21</volume><fpage>2491</fpage><lpage>2502</lpage><year>2017</year><pub-id pub-id-type="doi">10.1111/jcmm.13170</pub-id><pub-id pub-id-type="pmid">28382720</pub-id><pub-id pub-id-type="pmcid">5618698</pub-id></element-citation></ref>
<ref id="b8-ijmm-43-03-1331"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Bao</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Long noncoding RNA HOTAIR regulates autophagy via the miR-20b-5p/ATG7 axis in hepatic ischemia/reperfusion injury</article-title><source>Gene</source><volume>686</volume><fpage>56</fpage><lpage>62</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.gene.2018.10.059</pub-id></element-citation></ref>
<ref id="b9-ijmm-43-03-1331"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>MicroRNA-30a ameliorates hepatic fibrosis by inhibiting beclin1-mediated autophagy</article-title><source>J Cell Mol Med</source><volume>21</volume><fpage>3679</fpage><lpage>3692</lpage><year>2017</year><pub-id pub-id-type="doi">10.1111/jcmm.13278</pub-id><pub-id pub-id-type="pmid">28766848</pub-id><pub-id pub-id-type="pmcid">5706581</pub-id></element-citation></ref>
<ref id="b10-ijmm-43-03-1331"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>LP</given-names></name><name><surname>Glasner</surname><given-names>ME</given-names></name><name><surname>Yekta</surname><given-names>S</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Vertebrate microRNA genes</article-title><source>Science</source><volume>299</volume><fpage>1540</fpage><year>2003</year><pub-id pub-id-type="doi">10.1126/science.1080372</pub-id><pub-id pub-id-type="pmid">12624257</pub-id></element-citation></ref>
<ref id="b11-ijmm-43-03-1331"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>JB</given-names></name><name><surname>Eisenhardt</surname><given-names>SU</given-names></name><name><surname>Stark</surname><given-names>GB</given-names></name><name><surname>Bode</surname><given-names>C</given-names></name><name><surname>Moser</surname><given-names>M</given-names></name><name><surname>Grundmann</surname><given-names>S</given-names></name></person-group><article-title>MicroRNAs in ischemia-reperfusion injury</article-title><source>Am J Cardiovasc Dis</source><volume>2</volume><fpage>237</fpage><lpage>247</lpage><year>2012</year><pub-id pub-id-type="pmid">22937493</pub-id><pub-id pub-id-type="pmcid">3427975</pub-id></element-citation></ref>
<ref id="b12-ijmm-43-03-1331"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valinezhad Orang</surname><given-names>A</given-names></name><name><surname>Safaralizadeh</surname><given-names>R</given-names></name><name><surname>Kazemzadeh-Bavili</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation</article-title><source>Int J Genomics</source><volume>2014</volume><fpage>970607</fpage><year>2014</year><pub-id pub-id-type="doi">10.1155/2014/970607</pub-id><pub-id pub-id-type="pmid">25180174</pub-id><pub-id pub-id-type="pmcid">4142390</pub-id></element-citation></ref>
<ref id="b13-ijmm-43-03-1331"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name></person-group><article-title>MicroRNAs: An emerging player in autophagy</article-title><source>ScienceOpen Res</source><volume>2015</volume><fpage>14293/S2199</fpage><lpage>1006</lpage><year>2015</year></element-citation></ref>
<ref id="b14-ijmm-43-03-1331"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Metazoan MicroRNAs</article-title><source>Cell</source><volume>173</volume><fpage>20</fpage><lpage>51</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.006</pub-id><pub-id pub-id-type="pmid">29570994</pub-id><pub-id pub-id-type="pmcid">6091663</pub-id></element-citation></ref>
<ref id="b15-ijmm-43-03-1331"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Frankel</surname><given-names>LB</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><name><surname>H&#x000F8;yer-Hansen</surname><given-names>M</given-names></name><name><surname>Farkas</surname><given-names>T</given-names></name><name><surname>Krogh</surname><given-names>A</given-names></name><name><surname>J&#x000E4;&#x000E4;ttel&#x000E4;</surname><given-names>M</given-names></name><name><surname>Lund</surname><given-names>AH</given-names></name></person-group><article-title>microRNA-101 is a potent inhibitor of autophagy</article-title><source>EMBO J</source><volume>30</volume><fpage>4628</fpage><lpage>4641</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/emboj.2011.331</pub-id></element-citation></ref>
<ref id="b16-ijmm-43-03-1331"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valera</surname><given-names>E</given-names></name><name><surname>Spencer</surname><given-names>B</given-names></name><name><surname>Mott</surname><given-names>J</given-names></name><name><surname>Trejo</surname><given-names>M</given-names></name><name><surname>Adame</surname><given-names>A</given-names></name><name><surname>Mante</surname><given-names>M</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Desplats</surname><given-names>P</given-names></name></person-group><article-title>MicroRNA-101 modulates autophagy and oligodendroglial alpha-synuclein accumulation in multiple system atrophy</article-title><source>Front Mol Neurosci</source><volume>10</volume><fpage>329</fpage><year>2017</year><pub-id pub-id-type="doi">10.3389/fnmol.2017.00329</pub-id><pub-id pub-id-type="pmid">29089869</pub-id><pub-id pub-id-type="pmcid">5650998</pub-id></element-citation></ref>
<ref id="b17-ijmm-43-03-1331"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells</article-title><source>Oncol Rep</source><volume>29</volume><fpage>2019</fpage><lpage>2024</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/or.2013.2338</pub-id><pub-id pub-id-type="pmid">23483142</pub-id></element-citation></ref>
<ref id="b18-ijmm-43-03-1331"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Research Council (US) Institute for Laboratory Animal Research</collab></person-group><source>Guide for the Care and Use of Laboratory Animals</source><publisher-name>National Academies Press (US)</publisher-name><publisher-loc>Washington, DC</publisher-loc><year>1996</year></element-citation></ref>
<ref id="b19-ijmm-43-03-1331"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals</collab></person-group><source>Guide for the Care and Use of Laboratory Animals</source><publisher-name>National Academies Press (US)</publisher-name><publisher-loc>Washington, DC</publisher-loc><year>2011</year></element-citation></ref>
<ref id="b20-ijmm-43-03-1331"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Ke</surname><given-names>B</given-names></name><name><surname>Freitas</surname><given-names>MC</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Busuttil</surname><given-names>RW</given-names></name><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Kupiec-Weglinski</surname><given-names>JW</given-names></name></person-group><article-title>Programmed death-1/B7-H1 negative costimulation protects mouse liver against ischemia and reperfusion injury</article-title><source>Hepatology</source><volume>52</volume><fpage>1380</fpage><lpage>1389</lpage><year>2010</year><pub-id pub-id-type="doi">10.1002/hep.23843</pub-id><pub-id pub-id-type="pmid">20815020</pub-id><pub-id pub-id-type="pmcid">2947605</pub-id></element-citation></ref>
<ref id="b21-ijmm-43-03-1331"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>MC</given-names></name><name><surname>Olivier</surname><given-names>AK</given-names></name><name><surname>Jacobus</surname><given-names>JA</given-names></name><name><surname>Mapuskar</surname><given-names>KA</given-names></name><name><surname>Mao</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>SM</given-names></name><name><surname>Riley</surname><given-names>DP</given-names></name><name><surname>Gius</surname><given-names>D</given-names></name><name><surname>Spitz</surname><given-names>DR</given-names></name></person-group><article-title>Superoxide mediates acute liver injury in irradiated mice lacking sirtuin 3</article-title><source>Antioxid Redox Signal</source><volume>20</volume><fpage>1423</fpage><lpage>1435</lpage><year>2014</year><pub-id pub-id-type="doi">10.1089/ars.2012.5091</pub-id><pub-id pub-id-type="pmcid">3936509</pub-id></element-citation></ref>
<ref id="b22-ijmm-43-03-1331"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Toledo-Pereyra</surname><given-names>LH</given-names></name><name><surname>Rodriguez</surname><given-names>FJ</given-names></name><name><surname>Cejalvo</surname><given-names>D</given-names></name></person-group><article-title>Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. modulating effects of FK506 and cyclosporine</article-title><source>Transplantation</source><volume>55</volume><fpage>1265</fpage><lpage>1272</lpage><year>1993</year><pub-id pub-id-type="doi">10.1097/00007890-199306000-00011</pub-id><pub-id pub-id-type="pmid">7685932</pub-id></element-citation></ref>
<ref id="b23-ijmm-43-03-1331"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(&#x02212;Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></element-citation></ref>
<ref id="b24-ijmm-43-03-1331"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergne</surname><given-names>I</given-names></name><name><surname>Roberts</surname><given-names>E</given-names></name><name><surname>Elmaoued</surname><given-names>RA</given-names></name><name><surname>Tosch</surname><given-names>V</given-names></name><name><surname>Delgado</surname><given-names>MA</given-names></name><name><surname>Proikas-Cezanne</surname><given-names>T</given-names></name><name><surname>Laporte</surname><given-names>J</given-names></name><name><surname>Deretic</surname><given-names>V</given-names></name></person-group><article-title>Control of autophagy initiation by phosphoinositide 3-phosphatase jumpy</article-title><source>EMBO J</source><volume>28</volume><fpage>2244</fpage><lpage>2258</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/emboj.2009.159</pub-id><pub-id pub-id-type="pmid">19590496</pub-id><pub-id pub-id-type="pmcid">2726690</pub-id></element-citation></ref>
<ref id="b25-ijmm-43-03-1331"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sheng</surname><given-names>F</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells</article-title><source>Autophagy</source><volume>8</volume><fpage>1215</fpage><lpage>1226</lpage><year>2012</year><pub-id pub-id-type="doi">10.4161/auto.20284</pub-id><pub-id pub-id-type="pmid">22647982</pub-id></element-citation></ref>
<ref id="b26-ijmm-43-03-1331"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Current studies on therapeutic approaches for ischemia/reperfusion injury in steatotic livers</article-title><source>Hepatol Res</source><volume>38</volume><fpage>851</fpage><lpage>859</lpage><year>2008</year><pub-id pub-id-type="doi">10.1111/j.1872-034X.2008.00354.x</pub-id><pub-id pub-id-type="pmid">18507690</pub-id></element-citation></ref>
<ref id="b27-ijmm-43-03-1331"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CX</given-names></name><name><surname>Ng</surname><given-names>KT</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>XB</given-names></name><name><surname>Ling</surname><given-names>CC</given-names></name><name><surname>Ma</surname><given-names>YY</given-names></name><name><surname>Geng</surname><given-names>W</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Chung</surname><given-names>SK</given-names></name><etal/></person-group><article-title>The inhibition of aldose reductase attenuates hepatic ischemia-reperfusion injury through reducing inflammatory response</article-title><source>Ann Surg</source><volume>260</volume><fpage>317</fpage><lpage>328</lpage><year>2014</year><pub-id pub-id-type="doi">10.1097/SLA.0000000000000429</pub-id><pub-id pub-id-type="pmid">24699020</pub-id></element-citation></ref>
<ref id="b28-ijmm-43-03-1331"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohsumi</surname><given-names>Y</given-names></name></person-group><article-title>Historical landmarks of autophagy research</article-title><source>Cell Res</source><volume>24</volume><fpage>9</fpage><lpage>23</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/cr.2013.169</pub-id><pub-id pub-id-type="pmcid">3879711</pub-id></element-citation></ref>
<ref id="b29-ijmm-43-03-1331"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohsumi</surname><given-names>Y</given-names></name></person-group><article-title>Molecular dissection of autophagy: Two ubiquitin-like systems</article-title><source>Nat Rev Mol Cell Biol</source><volume>2</volume><fpage>211</fpage><lpage>216</lpage><year>2001</year><pub-id pub-id-type="doi">10.1038/35056522</pub-id><pub-id pub-id-type="pmid">11265251</pub-id></element-citation></ref>
<ref id="b30-ijmm-43-03-1331"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidberg</surname><given-names>H</given-names></name><name><surname>Shpilka</surname><given-names>T</given-names></name><name><surname>Shvets</surname><given-names>E</given-names></name><name><surname>Abada</surname><given-names>A</given-names></name><name><surname>Shimron</surname><given-names>F</given-names></name><name><surname>Elazar</surname><given-names>Z</given-names></name></person-group><article-title>LC3 and GATE-16 N termini mediate membrane fusion processes required for autophagosome biogenesis</article-title><source>Dev Cell</source><volume>20</volume><fpage>444</fpage><lpage>454</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.devcel.2011.02.006</pub-id><pub-id pub-id-type="pmid">21497758</pub-id></element-citation></ref>
<ref id="b31-ijmm-43-03-1331"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name></person-group><article-title>MicroRNA-17 regulates autophagy to promote hepatic ischemia/reperfusion injury via suppression of signal transductions and activation of transcription-3 expression</article-title><source>Liver Transpl</source><volume>22</volume><fpage>1697</fpage><lpage>1709</lpage><year>2016</year><pub-id pub-id-type="doi">10.1002/lt.24606</pub-id><pub-id pub-id-type="pmid">27541946</pub-id></element-citation></ref>
<ref id="b32-ijmm-43-03-1331"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>JL</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name></person-group><article-title>Liver autophagy: Much more than just taking out the trash</article-title><source>Nat Rev Gastroenterol Hepatol</source><volume>11</volume><fpage>187</fpage><lpage>200</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/nrgastro.2013.211</pub-id><pub-id pub-id-type="pmcid">3980679</pub-id></element-citation></ref>
<ref id="b33-ijmm-43-03-1331"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>CS</given-names></name><name><surname>Huh</surname><given-names>WK</given-names></name></person-group><article-title>Bidirectional regulation between TORC1 and autophagy in saccharomyces cerevisiae</article-title><source>Autophagy</source><volume>7</volume><fpage>854</fpage><lpage>862</lpage><year>2011</year><pub-id pub-id-type="doi">10.4161/auto.7.8.15696</pub-id><pub-id pub-id-type="pmid">21490424</pub-id></element-citation></ref>
<ref id="b34-ijmm-43-03-1331"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Baicalein pretreatment reduces liver ischemia/reperfusion injury via induction of autophagy in rats</article-title><source>Sci Rep</source><volume>6</volume><fpage>25042</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep25042</pub-id><pub-id pub-id-type="pmid">27150843</pub-id><pub-id pub-id-type="pmcid">4858649</pub-id></element-citation></ref>
<ref id="b35-ijmm-43-03-1331"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name></person-group><article-title>miR-155 aggravates liver ischemia/reperfusion injury by suppressing SOCS1 in mice</article-title><source>Transplant Proc</source><volume>50</volume><fpage>3831</fpage><lpage>3839</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.transproceed.2018.08.060</pub-id><pub-id pub-id-type="pmid">30577275</pub-id></element-citation></ref>
<ref id="b36-ijmm-43-03-1331"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>QF</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>BQ</given-names></name><name><surname>Xia</surname><given-names>ZP</given-names></name><name><surname>Liu</surname><given-names>ZZ</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>YF</given-names></name></person-group><article-title>Mild hypothermia pretreatment protects hepatocytes against ischemia reperfusion injury via down-regulating miR-122 and IGF-1R/AKT pathway</article-title><source>Cryobiology</source><volume>75</volume><fpage>100</fpage><lpage>105</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.cryobiol.2017.01.005</pub-id><pub-id pub-id-type="pmid">28093198</pub-id></element-citation></ref>
<ref id="b37-ijmm-43-03-1331"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Novel targets for treating ischemia-reperfusion injury in the liver</article-title><source>Int J Mol Sci</source><volume>19</volume><fpage>E1302</fpage><year>2018</year><pub-id pub-id-type="doi">10.3390/ijms19051302</pub-id><pub-id pub-id-type="pmid">29701719</pub-id><pub-id pub-id-type="pmcid">5983804</pub-id></element-citation></ref>
<ref id="b38-ijmm-43-03-1331"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SP</given-names></name><name><surname>He</surname><given-names>JD</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>SY</given-names></name><name><surname>Zhang</surname><given-names>HM</given-names></name><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Shen</surname><given-names>ZY</given-names></name></person-group><article-title>miR-30b inhibits autophagy to alleviate hepatic ischemia-reperfusion injury via decreasing the Atg12-Atg5 conjugate</article-title><source>World J Gastroenterol</source><volume>22</volume><fpage>4501</fpage><lpage>4514</lpage><year>2016</year><pub-id pub-id-type="doi">10.3748/wjg.v22.i18.4501</pub-id><pub-id pub-id-type="pmid">27182160</pub-id><pub-id pub-id-type="pmcid">4858632</pub-id></element-citation></ref>
<ref id="b39-ijmm-43-03-1331"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Joe</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Jeong</surname><given-names>SO</given-names></name><name><surname>Mani</surname><given-names>N</given-names></name><name><surname>Cho</surname><given-names>GJ</given-names></name><name><surname>Pae</surname><given-names>HO</given-names></name><name><surname>Ryter</surname><given-names>SW</given-names></name><name><surname>Chung</surname><given-names>HT</given-names></name></person-group><article-title>Carbon monoxide protects against hepatic ischemia/reperfusion injury by modulating the miR-34a/SIRT1 pathway</article-title><source>Biochim Biophys Acta</source><volume>1852</volume><fpage>1550</fpage><lpage>1559</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbadis.2015.04.017</pub-id><pub-id pub-id-type="pmid">25916635</pub-id></element-citation></ref>
<ref id="b40-ijmm-43-03-1331"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zu</surname><given-names>G</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Shan</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name></person-group><article-title>miR-34a-5p inhibition alleviates intestinal ischemia/reperfusion-induced reactive oxygen species accumulation and apoptosis via activation of SIRT1 signaling</article-title><source>Antioxid Redox Signal</source><volume>24</volume><fpage>961</fpage><lpage>973</lpage><year>2016</year><pub-id pub-id-type="doi">10.1089/ars.2015.6492</pub-id><pub-id pub-id-type="pmid">26935288</pub-id></element-citation></ref>
<ref id="b41-ijmm-43-03-1331"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasudevan</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Steitz</surname><given-names>JA</given-names></name></person-group><article-title>Switching from repression to activation: microRNAs can up-regulate translation</article-title><source>Science</source><volume>318</volume><fpage>1931</fpage><lpage>1934</lpage><year>2007</year><pub-id pub-id-type="doi">10.1126/science.1149460</pub-id><pub-id pub-id-type="pmid">18048652</pub-id></element-citation></ref>
<ref id="b42-ijmm-43-03-1331"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carthew</surname><given-names>RW</given-names></name><name><surname>Sontheimer</surname><given-names>EJ</given-names></name></person-group><article-title>Origins and Mechanisms of miRNAs and siRNAs</article-title><source>Cell</source><volume>136</volume><fpage>642</fpage><lpage>655</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.035</pub-id><pub-id pub-id-type="pmid">19239886</pub-id><pub-id pub-id-type="pmcid">2675692</pub-id></element-citation></ref>
<ref id="b43-ijmm-43-03-1331"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siomi</surname><given-names>H</given-names></name><name><surname>Siomi</surname><given-names>MC</given-names></name></person-group><article-title>On the road to reading the RNA-interference code</article-title><source>Nature</source><volume>457</volume><fpage>396</fpage><lpage>404</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/nature07754</pub-id><pub-id pub-id-type="pmid">19158785</pub-id></element-citation></ref>
<ref id="b44-ijmm-43-03-1331"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Addison</surname><given-names>JB</given-names></name><name><surname>Wonderlin</surname><given-names>WF</given-names></name><name><surname>Ivanov</surname><given-names>AV</given-names></name><name><surname>Ruppert</surname><given-names>JM</given-names></name></person-group><article-title>A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context</article-title><source>Mol Cell Biol</source><volume>31</volume><fpage>2513</fpage><lpage>2527</lpage><year>2011</year><pub-id pub-id-type="doi">10.1128/MCB.01189-10</pub-id><pub-id pub-id-type="pmid">21518959</pub-id><pub-id pub-id-type="pmcid">3133414</pub-id></element-citation></ref>
<ref id="b45-ijmm-43-03-1331"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasudevan</surname><given-names>S</given-names></name><name><surname>Steitz</surname><given-names>JA</given-names></name></person-group><article-title>AU-rich-element-mediated upregulation of translation by FXR1 and argonaute 2</article-title><source>Cell</source><volume>128</volume><fpage>1105</fpage><lpage>1118</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.cell.2007.01.038</pub-id><pub-id pub-id-type="pmid">17382880</pub-id><pub-id pub-id-type="pmcid">3430382</pub-id></element-citation></ref>
<ref id="b46-ijmm-43-03-1331"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshiri</surname><given-names>F</given-names></name><name><surname>Salvi</surname><given-names>A</given-names></name><name><surname>Gramantieri</surname><given-names>L</given-names></name><name><surname>Sangiovanni</surname><given-names>A</given-names></name><name><surname>Guerriero</surname><given-names>P</given-names></name><name><surname>De Petro</surname><given-names>G</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Lupini</surname><given-names>L</given-names></name><name><surname>Sattari</surname><given-names>A</given-names></name><name><surname>Cheung</surname><given-names>D</given-names></name><etal/></person-group><article-title>Circulating miR-106b-3p miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma</article-title><source>Oncotarget</source><volume>9</volume><fpage>15350</fpage><lpage>15364</lpage><year>2018</year><pub-id pub-id-type="doi">10.18632/oncotarget.24601</pub-id><pub-id pub-id-type="pmid">29632649</pub-id><pub-id pub-id-type="pmcid">5880609</pub-id></element-citation></ref>
<ref id="b47-ijmm-43-03-1331"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Beckebaum</surname><given-names>S</given-names></name><name><surname>Iacob</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Kaiser</surname><given-names>GM</given-names></name><name><surname>Radtke</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Kabar</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>HH</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity</article-title><source>J Hepatol</source><volume>60</volume><fpage>590</fpage><lpage>598</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jhep.2013.10.028</pub-id></element-citation></ref>
<ref id="b48-ijmm-43-03-1331"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name></person-group><article-title>MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR</article-title><source>Cancer Biomark</source><volume>21</volume><fpage>179</fpage><lpage>186</lpage><year>2017</year><pub-id pub-id-type="doi">10.3233/CBM-170620</pub-id><pub-id pub-id-type="pmid">29081412</pub-id></element-citation></ref>
<ref id="b49-ijmm-43-03-1331"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxton</surname><given-names>RA</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><article-title>mTOR signaling in growth, metabolism, and disease</article-title><source>Cell</source><volume>168</volume><fpage>960</fpage><lpage>976</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.004</pub-id><pub-id pub-id-type="pmid">28283069</pub-id><pub-id pub-id-type="pmcid">5394987</pub-id></element-citation></ref>
<ref id="b50-ijmm-43-03-1331"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group><article-title>Octreotide alleviates autophagy by up-regulation of MicroRNA-101 in intestinal epithelial cell line caco-2</article-title><source>Cell Physiol Biochem</source><volume>49</volume><fpage>1352</fpage><lpage>1363</lpage><year>2018</year><pub-id pub-id-type="doi">10.1159/000493413</pub-id><pub-id pub-id-type="pmid">30205395</pub-id></element-citation></ref>
<ref id="b51-ijmm-43-03-1331"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>LS</given-names></name></person-group><article-title>PCNA tightens its hold on the nucleus</article-title><source>Cell Cycle</source><volume>14</volume><fpage>2727</fpage><lpage>2728</lpage><year>2015</year><pub-id pub-id-type="doi">10.1080/15384101.2015.1064699</pub-id><pub-id pub-id-type="pmid">26176941</pub-id><pub-id pub-id-type="pmcid">4613660</pub-id></element-citation></ref>
<ref id="b52-ijmm-43-03-1331"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melo</surname><given-names>RM</given-names></name><name><surname>Martins</surname><given-names>YS</given-names></name><name><surname>Luz</surname><given-names>RK</given-names></name><name><surname>Rizzo</surname><given-names>E</given-names></name><name><surname>Bazzoli</surname><given-names>N</given-names></name></person-group><article-title>PCNA and apoptosis during post-spawning ovarian remodeling in the teleost oreochromis niloticus</article-title><source>Tissue Cell</source><volume>47</volume><fpage>541</fpage><lpage>549</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.tice.2015.10.002</pub-id><pub-id pub-id-type="pmid">26542933</pub-id></element-citation></ref>
<ref id="b53-ijmm-43-03-1331"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghavami</surname><given-names>S</given-names></name><name><surname>Hashemi</surname><given-names>M</given-names></name><name><surname>Ande</surname><given-names>SR</given-names></name><name><surname>Yeganeh</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Eshraghi</surname><given-names>M</given-names></name><name><surname>Bus</surname><given-names>CJ</given-names></name><name><surname>Kadkhoda</surname><given-names>K</given-names></name><name><surname>Wiechec</surname><given-names>E</given-names></name><name><surname>Halayko</surname><given-names>AJ</given-names></name><name><surname>Los</surname><given-names>M</given-names></name></person-group><article-title>Apoptosis and cancer: Mutations within caspase genes</article-title><source>J Med Genet</source><volume>46</volume><fpage>497</fpage><lpage>510</lpage><year>2009</year><pub-id pub-id-type="doi">10.1136/jmg.2009.066944</pub-id><pub-id pub-id-type="pmid">19505876</pub-id></element-citation></ref>
<ref id="b54-ijmm-43-03-1331"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikoonahad Lotfabadi</surname><given-names>N</given-names></name><name><surname>Mohseni Kouchesfahani</surname><given-names>H</given-names></name><name><surname>Sheikhha</surname><given-names>MH</given-names></name><name><surname>Kalantar</surname><given-names>SM</given-names></name></person-group><article-title>In vitro transfection of anti-tumor miR-101 induces BIM, a pro-apoptotic protein, expression in acute myeloid leukemia (AML)</article-title><source>EXCLI J</source><volume>16</volume><fpage>1257</fpage><lpage>1267</lpage><year>2017</year></element-citation></ref>
<ref id="b55-ijmm-43-03-1331"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><article-title>An expanding role for mTOR in cancer</article-title><source>Trends Mol Med</source><volume>11</volume><fpage>353</fpage><lpage>361</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.molmed.2005.06.007</pub-id><pub-id pub-id-type="pmid">16002336</pub-id></element-citation></ref>
<ref id="b56-ijmm-43-03-1331"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>RC</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy</article-title><source>Cell</source><volume>152</volume><fpage>290</fpage><lpage>303</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.cell.2012.12.016</pub-id><pub-id pub-id-type="pmid">23332761</pub-id><pub-id pub-id-type="pmcid">3587159</pub-id></element-citation></ref>
<ref id="b57-ijmm-43-03-1331"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kundu</surname><given-names>M</given-names></name><name><surname>Viollet</surname><given-names>B</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1</article-title><source>Nat Cell Biol</source><volume>13</volume><fpage>132</fpage><lpage>141</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/ncb2152</pub-id><pub-id pub-id-type="pmid">21258367</pub-id><pub-id pub-id-type="pmcid">3987946</pub-id></element-citation></ref>
<ref id="b58-ijmm-43-03-1331"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Deng</surname><given-names>MF</given-names></name><name><surname>Wei</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>DQ</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>JZ</given-names></name><etal/></person-group><article-title>Targeting the HDAC2/HNF-4A/miR-101b/AMPK pathway rescues tauopathy and dendritic abnormalities in alzheimer's disease</article-title><source>Mol Ther</source><volume>25</volume><fpage>752</fpage><lpage>764</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.01.018</pub-id><pub-id pub-id-type="pmid">28202389</pub-id><pub-id pub-id-type="pmcid">5363202</pub-id></element-citation></ref>
<ref id="b59-ijmm-43-03-1331"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name></person-group><article-title>mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK</article-title><source>Oncotarget</source><volume>7</volume><fpage>35188</fpage><lpage>35198</lpage><year>2016</year><pub-id pub-id-type="pmid">27145268</pub-id><pub-id pub-id-type="pmcid">5085220</pub-id></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ijmm-43-03-1331" position="float">
<label>Figure 1</label>
<caption>
<p>Alterations of miR-101 expression and autophagy signaling in the liver IR injury mouse model. (A) Relative expression levels of miR-101 and mTOR mRNA in mouse liver at each reperfusion time point were detected using reverse transcription-quantitative polymerase chain reaction. <sup>&#x0002A;</sup>P&#x0003C;0.05 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. miR-101 sham. <sup>#</sup>P&#x0003C;0.05 and <sup>###</sup>P&#x0003C;0.001 vs. mTOR sham. (B) Comparison of serum ALT and AST levels at different time points. <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. ALT sham. <sup>###</sup>P&#x0003C;0.001 vs. AST sham. (C) Western blots exhibiting the levels of mTOR, p-mTOR, caspase-3, p62 and LC3II proteins in the liver at different time points post-reperfusion. GAPDH was used as the internal control. <sup>&#x0002A;</sup>P&#x0003C;0.05, <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. the sham treated group. miR, microRNA; mTOR, mechanistic target of rapamycin; IR, ischemia/reperfusion; ALT, alanine aminotransferase; AST, aspartate aminotransferase; p-, phosphorylated; LC3II, microtubule-associated protein 1 light II.</p></caption>
<graphic xlink:href="IJMM-43-03-1331-g00.tif"/></fig>
<fig id="f2-ijmm-43-03-1331" position="float">
<label>Figure 2</label>
<caption>
<p>Histopathological changes during liver IR injury. (A) Representative images of H&#x00026;E-stained liver sections presenting characteristic histopathological changes associated with IR (&#x000D7;200 magnification; left panel), black arrows indicate hepatocyte edema, apoptosis and necrosis observed after 6 and 12 h reperfusion. Scale bars=50 <italic>&#x000B5;</italic>m. Column graph comparing the Suzuki's score of IR-induced liver injury in all groups (right). <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. the sham-treated group. (B) Representative immunohistochemistry images revealing the expression of caspase-3 and PCNA (&#x000D7;200 magnification; scale bars=50 <italic>&#x000B5;</italic>m; left panel). Column graph comparing the percentage of caspase-3 and PCNA positive cells in different groups (right). <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. caspase-3 sham. <sup>##</sup>P&#x0003C;0.01 and <sup>###</sup>P&#x0003C;0.001 vs. PCNA sham. (C) Representative images presenting TUNEL-positive apoptotic nuclei (red) with DAPI counterstaining (&#x000D7;200 magnification; scale bars=50 <italic>&#x000B5;</italic>m; left panel). Column graph comparing the percentage of TUNEL-positive cells in the liver analyzed using Image J software (right). <sup>&#x0002A;</sup>P&#x0003C;0.05, <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. the sham-treated group. IR, ischemia/reperfusion; H&#x00026;E, haemotoxylin and eosin; PCNA, proliferating cell nuclear antigen; TUNEL, terminal uridine nick-end labeling; DAPI, 3,3&#x02032;-diaminobenzidine.</p></caption>
<graphic xlink:href="IJMM-43-03-1331-g01.tif"/></fig>
<fig id="f3-ijmm-43-03-1331" position="float">
<label>Figure 3</label>
<caption>
<p>miR-101 ameliorates liver IR injury by inhibiting apoptosis. (A) Relative expression levels of miR-101 and mTOR mRNA in response to miR-101 agomir/antagomir were detected using reverse transcription-quantitative polymerase chain reaction. <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. miR-101 miR-NC group. <sup>##</sup>P&#x0003C;0.01 and <sup>###</sup>P&#x0003C;0.001 vs. mTOR miR-NC group. (B) Representative images of haemotoxylin and eosin-stained liver sections presenting histopathological changes (&#x000D7;200 magnification; scale bars=50 <italic>&#x000B5;</italic>m) following miR-101 agomir or antagomir injection. <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. miR-NC group. (C) Western blots presenting mTOR, caspase-3 and LC3II levels in the liver. <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. the miR-NC group. (D) Representative images of TUNEL stained apoptotic nuclei (red) with DAPI counterstaining (&#x000D7;200 magnification; scale bars=50 <italic>&#x000B5;</italic>m), and comparison of the percentage of apoptotic cells analyzed using Image J software. <sup>&#x0002A;</sup>P&#x0003C;0.05 and <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 with comparisons shown by lines. miR, microRNA; mTOR, mechanistic target of rapamycin; NC, negative control; IR, ischemia/reperfusion; LC3II, microtubule-associated protein 1 light II; TUNEL, terminal uridine nick-end labeling; DAPI, 3,3&#x02032;-diaminobenzidine.</p></caption>
<graphic xlink:href="IJMM-43-03-1331-g02.tif"/></fig>
<fig id="f4-ijmm-43-03-1331" position="float">
<label>Figure 4</label>
<caption>
<p>Inhibition of autophagy enhances the protective effect of miR-101 on liver IR injury. (A) Histopathological changes in liver tissue subsequent to treatment with autophagy inhibitor (3-MA; &#x000D7;200 magnification). Scale bars=50 <italic>&#x000B5;</italic>m. <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. IR group. (B) Representative immunohistochemistry images of liver tissues presenting nuclear staining of PCNA (&#x000D7;200 magnification; scale bars=50 <italic>&#x000B5;</italic>m), and comparisons of the percentage of PCNA-stained cells in different groups. <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 with comparisons shown by lines. (C) Representative images of TUNEL stained (red nuclei) apoptotic cells with DAPI counter-staining (&#x000D7;200 magnification; scale bars=50 <italic>&#x000B5;</italic>m), and the percentage of TUNEL positive cells analyzed using Image J software. <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 with comparisons shown by lines. (D) Western blots presenting LC3II, p62 and caspase-3 protein levels. <sup>&#x0002A;</sup>P&#x0003C;0.05 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. the IR group. (E) Comparison of serum ALT and AST in different groups. <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 with comparisons shown by lines. <sup>###</sup>P&#x0003C;0.001 with comparisons shown by lines. miR, microRNA; IR, ischemia/reperfusion; 3-MA, 3-methyladenine; PCNA, proliferating cell nuclear antigen; H&#x00026;E, haemotoxylin and eosin; TUNEL, terminal uridine nick-end labeling; DAPI, 3,3&#x02032;-diaminobenzidine; LC3II, microtubule-associated protein 1 light II; ALT, alanine aminotransferase; AST, aspartate aminotransferase.</p></caption>
<graphic xlink:href="IJMM-43-03-1331-g03.tif"/></fig>
<fig id="f5-ijmm-43-03-1331" position="float">
<label>Figure 5</label>
<caption>
<p>miR-101 inhibits autophagy and weakens IR injury by activating the mTOR pathway <italic>in vitro</italic>. (A) Relative expression levels of miR-101 and mTOR mRNA in response to miR-101 mimetics/inhibitors. <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. the miR-101 NC group. <sup>##</sup>P&#x0003C;0.01 and <sup>###</sup>P&#x0003C;0.001 vs. the mTOR NC group. (B) Western blots presenting mTOR, caspase-3 and LC3II levels in AML12 cells. <sup>&#x0002A;</sup>P&#x0003C;0.05, <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. NC group. (C) Representative confocal images of immunofluorescent GFP-RFP-LC3 expression in AML12 cells. Yellow dots indicate the autophagosomes with GFP and RFP merging, and the red dots represent the autolysosomes with degraded GFP due to the acidic environment. Scale bars=5 <italic>&#x000B5;</italic>m. <sup>&#x0002A;</sup>P&#x0003C;0.05, <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 with comparisons shown by lines. (D) Representative immunofluorescence images presenting the expression of p62 in AML12 at &#x000D7;400 magnification. Scale bars=20 <italic>&#x000B5;</italic>m. miR, microRNA; mTOR, mechanistic target of rapamycin; NC, negative control; LC3II, microtubule-associated protein 1 light II; IR, ischemia/reperfusion; GFP, green fluorescence protein; RFP, red fluorescence protein; DAPI, 3,3&#x02032;-diaminobenzidine.</p></caption>
<graphic xlink:href="IJMM-43-03-1331-g04.tif"/></fig>
<fig id="f6-ijmm-43-03-1331" position="float">
<label>Figure 6</label>
<caption>
<p>Inhibition of miR-101 and mTOR expression aggravates liver IR injury. (A) Western blots presenting mTOR, p-mTOR, caspase-3, p62 and LC3II levels in AML12 cells. (B) Column graph presenting the percentage of surviving cells in each treatment group. <sup>&#x0002A;&#x0002A;</sup>P&#x0003C;0.01 and <sup>&#x0002A;&#x0002A;&#x0002A;</sup>P&#x0003C;0.001 vs. the IR group. miR, microRNA; mTOR, mechanistic target of rapamycin; IR, ischemia/reperfusion; p-, phosphorylated; LC3II, microtubule-associated protein 1 light II; Rapa, rapamycin.</p></caption>
<graphic xlink:href="IJMM-43-03-1331-g05.tif"/></fig>
<table-wrap id="tI-ijmm-43-03-1331" position="float">
<label>Table I</label>
<caption>
<p>Suzuki scores for liver ischemia/reperfusion injury.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Numerical assessment</th>
<th valign="top" align="center">Congestion</th>
<th valign="top" align="center">Vacuolization</th>
<th valign="top" align="center">Necrosis</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">0</td>
<td valign="top" align="left">None</td>
<td valign="top" align="left">None</td>
<td valign="top" align="left">None</td></tr>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="left">Minimal (10%)</td>
<td valign="top" align="left">Minimal (10%)</td>
<td valign="top" align="left">Single-cell necrosis</td></tr>
<tr>
<td valign="top" align="left">2</td>
<td valign="top" align="left">Mild (11-30%)</td>
<td valign="top" align="left">Mild (11-30%)</td>
<td valign="top" align="left">Mild (&#x0003C;30%)</td></tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="left">Moderate (31-60%)</td>
<td valign="top" align="left">Moderate (31-60%)</td>
<td valign="top" align="left">Moderate (31&#x02013;60%)</td></tr></tbody></table></table-wrap></floats-group></article>
